FDA Peptide Reclassification 2026: Which Peptides Are Coming Back | Guides | Peptide Database

Summary

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 peptides previously restricted under the FDA’s Category 2 list would return to Category 1 status. This reverses a September 2023 decision that effectively banned compounding pharmacies from preparing widely used therapeutic peptides.

What’s Changing

14 peptides returning to legal compounding including BPC-157, TB-500, Thymosin Alpha-1, Ipamorelin, Selank, Semax, and GHK-Cu

5 peptides likely staying restricted including Melanotan II, GHRP-2, GHRP-6, LL-37, and PEG-MGF

Category 1 means licensed compounding pharmacies can legally prepare these peptides under physician prescription

This is NOT FDA approval — no peptide on this list has completed the clinical trial process required for drug approval

Current Status (March 30, 2026)

The FDA has not yet published its formal updated list. Kennedy’s announcement signals what is coming, but compounding pharmacies technically remain unauthorized to compound these substances until the official publication drops.

Check interactions between any of these peptides →

The 19 Peptides: Where They Stand

In September 2023, the FDA moved 19 peptides from Category 1 to Category 2 on its Bulk Drug Substances Under Evaluation list. The stated rationale: “immunogenicity risk, peptide-related impurities, and limited human safety data.”

The impact was immediate. Compounding pharmacies pulled these peptides from their shelves. Clinics that had built practices around peptide therapy lost access to their most prescribed compounds. Patients mid-protocol had their treatments interrupted. The gray market exploded.

Kennedy’s position on the original decision was blunt: “The Category 2 designations effectively created and accelerated the very gray market they were designed to prevent.”

Returning to Category 1 (Legal Compounding)

These peptides are expected to regain compounding eligibility:

BPC-157

Healing

Extensively studied (preclinical)

Tissue repair, gut healing, inflammation

TB-500

Well studied

Wound healing, muscle recovery

Thymosin Alpha-1

Immune

Immune modulation, approved in 35+ countries

AOD-9604

Metabolic

Fat metabolism, formerly TGA-approved in Australia

Ipamorelin

Growth Hormone

GH secretion, body composition, sleep

CJC-1295

GH release (status contested — see below)

Selank

Cognitive

Anxiety, cognitive function, approved in Russia

Semax

Neuroprotection, approved in Russia/Ukraine

GHK-Cu

Skin/Healing

Collagen synthesis, wound healing, hair growth

KPV

Emerging

Anti-inflammatory, gut inflammation

MOTS-c

Longevity

Mitochondrial function, insulin sensitivity

Epitalon

Telomerase activation, pineal regulation

Kisspeptin-10

Hormonal

Reproductive hormone regulation

DSIP

Sleep

Sleep architecture, stress response

Likely Staying Restricted (Category 2)

Five peptides appear likely to remain on the restricted list due to safety concerns, misuse potential, or proximity to existing FDA-approved drug categories:

Melanotan II

Cardiovascular + melanoma risk

Linked to nausea, blood pressure changes, and potential melanocyte stimulation raising skin cancer concerns

GHRP-2

Complex side effects

Elevates cortisol and prolactin — unlike Ipamorelin which is selective for GH only

GHRP-6

Same cortisol/prolactin concerns as GHRP-2, plus significant appetite stimulation

LL-37

Limited safety data

Antimicrobial peptide with very limited human safety data for systemic compounding use

PEG-MGF

Limited clinical evidence

PEGylated growth factor with minimal published human data

Worth noting: Thymosin Alpha-1 has the strongest clinical backing of any peptide on this list. It’s approved as a prescription drug in over 35 countries for hepatitis B and C treatment and as an immune adjuvant. Selank and Semax are both approved pharmaceuticals in Russia. The Category 2 restriction on these compounds was always harder to justify than for something like PEG-MGF, which has almost no published human data.

What Category 1 Actually Means (and Doesn’t Mean)

The Category 1 vs Category 2 distinction controls whether compounding pharmacies can legally prepare a substance. That’s it. People are treating this announcement like the FDA just approved 14 new drugs. They didn’t.

Category 1 allows:

Licensed compounding pharmacies (503A and 503B) to legally prepare the peptide

Physicians to prescribe it through a compounding pharmacy

Quality-controlled, pharmaceutical-grade preparations with certificates of analysis

Regulatory oversight of the compounding process

Category 1 does NOT mean:

FDA drug approval (that requires Phase I-III clinical trials, NDA submission, and years of review)

Over-the-counter availability

Insurance coverage (these remain cash-pay, typically $300-700 per compound)

That the peptide has been proven safe and effective in rigorous human trials

That “research use only” gray-market products are suddenly legitimate

The Gray Market Problem

Kennedy’s argument for reclassification had a pragmatic core: the Category 2 restrictions didn’t stop people from using these peptides. They just pushed demand underground.

When compounding pharmacies lost the ability to prepare BPC-157 and TB-500, patients didn’t stop wanting them. They turned to “research chemical” suppliers, overseas pharmacies, and unregulated online vendors selling peptides labeled “for research purposes only.” No physician oversight. No quality testing. No dosing guidance. No recourse if something went wrong.

The compounding pharmacy industry had quality controls: USP 797/795 compliance, PCAB accreditation, potency verification, sterility testing. The gray market has none of that. A 2024 analysis of gray-market peptide products found significant variability in actual peptide content versus label claims, contamination with bacterial endotoxins, and in some cases, entirely wrong compounds in the vial.

Reclassification to Category 1 doesn’t validate these peptides as proven treatments. It does restore the regulated supply chain that provides basic quality assurance.

The Supplement Angle

A separate but related push is happening simultaneously. On March 27, 2026, multiple outlets reported that dietary supplement manufacturers are lobbying the FDA to classify certain peptides as dietary supplement ingredients under the Dietary Supplement Health and Education Act (DSHEA).

This is a different regulatory pathway entirely. DSHEA allows supplement companies to sell products without pre-market approval as long as they don’t make drug claims. If peptides like BPC-157 were classified as dietary supplements, they could be sold over the counter without a prescription.

The peptide therapy community is split on this. Proponents argue it would dramatically increase access. Critics argue it would remove the physician oversight that makes peptide therapy reasonably safe, and that supplement-grade manufacturing doesn’t meet the purity standards needed for injectable compounds.

For now, the reclassification and the supplement push are separate tracks. Category 1 status restores the physician-prescription-plus-compounding-pharmacy model. The supplement pathway would bypass that model entirely.

What This Means If You’re Considering Peptide Therapy

If you’ve been using gray-market peptides, reclassification gives you a better option. Once the formal FDA publication drops:

Find a physician who prescribes peptide therapy. Telehealth peptide clinics exist in most states

Get bloodwork first. Baseline labs before starting any peptide protocol. The interaction checker can flag potential conflicts with other compounds you’re using

Use a licensed compounding pharmacy — specifically one that’s PCAB-accredited and FDA-registered. They’ll provide certificates of analysis verifying potency and sterility

Expect to pay out of pocket. Insurance doesn’t cover compounded peptides. Typical costs run $300-700 per compound depending on the peptide and pharmacy

If you’ve been waiting for legal access before trying peptides, this is the pathway. Not the gray market. Not “research chemical” vendors. A licensed physician and a regulated pharmacy.

Timeline and What to Watch

September 29, 2023

FDA moves 19 peptides to Category 2, restricting compounding

2024

Gray market explodes; compounding pharmacy industry pushes back

February 27, 2026

HHS Secretary Kennedy announces reclassification on Joe Rogan Experience #2461

March 2026

Formal FDA publication expected but not yet released

TBD

Official Category 1 reinstatement takes effect

The gap between announcement and implementation matters. Until the FDA actually publishes the updated list, compounding pharmacies cannot legally resume production. Kennedy said “within a couple of weeks” on February 27. It’s now March 30. The publication is overdue but reportedly still in process.

When it drops, expect a rush. Compounding pharmacies will need time to source raw materials, validate batches, and restart production. Don’t expect instant availability.

Frequently Asked Questions

Is BPC-157 legal again in 2026?

Not yet. HHS Secretary Kennedy announced that BPC-157 will return to Category 1 status, allowing licensed compounding pharmacies to legally prepare it under physician prescription. The formal FDA publication hasn’t been released as of March 30, 2026. Once published, BPC-157 will be legally accessible through compounding pharmacies but will still require a prescription.

Which peptides are staying banned?

Approximately 5 peptides are expected to remain on Category 2: Melanotan II (melanoma and cardiovascular concerns), GHRP-2 and GHRP-6 (cortisol and prolactin elevation), LL-37 (limited human safety data), and PEG-MGF (minimal clinical evidence). The CJC-1295 status is disputed between sources.

Can I buy peptides over the counter after reclassification?

No. Category 1 status means compounding pharmacies can prepare these peptides with a valid physician prescription. It does not mean over-the-counter availability. A separate push by supplement manufacturers to classify peptides under DSHEA could eventually allow OTC sales, but that’s a different regulatory track.

Are compounded peptides as good as pharmaceutical-grade drugs?

Compounding pharmacies operating under USP 797/795 standards produce pharmaceutical-grade preparations with potency and sterility testing. They are subject to state pharmacy board oversight and, for 503B outsourcing facilities, FDA inspection. This is significantly better than gray-market “research chemical” products, but compounded drugs have not undergone the same clinical trial process as FDA-approved drugs.

What should I do right now?

Wait for the formal FDA publication before seeking these peptides from compounding pharmacies. In the meantime, find a physician familiar with peptide therapy, get baseline bloodwork, and use the interaction checker to evaluate any stack you’re considering. When access resumes, you’ll have a provider relationship and lab baseline in place.

Peptide Database

Peptide Database provides research-based information on peptides, dosing protocols, and scientific references for educational purposes.

Related Guides

BPC-157 Human Clinical Trials (2025-2026): Complete Status & Results

Every BPC-157 human study published to date and what the evidence actually shows.

BPC-157 Side Effects: Is It Safe?

Research-based safety profile and risk assessment for BPC-157.